However, this safety management experience was conducted before the significant progress in understanding the fundamental pathophysiology of hyperglycemia secondary to pasireotide treatment, not considering the “glucagon-like peptide (GLP-1) pathway”, which appeared later in healthy volunteers to be involved as main mechanism of pasireotide-induced hyperglycemia [14, 15, 31–35]. This evidence concerns the gene GLP1R and Hyperglycemia.